Isolation  ||| S:0 E:10 ||| NNP
and  ||| S:10 E:14 ||| CC
comparison  ||| S:14 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
mesenchymal  ||| S:28 E:40 ||| NNS
stem  ||| S:40 E:45 ||| VBP
cell‑like  ||| S:45 E:55 ||| CD
cells  ||| S:55 E:61 ||| NNS
derived  ||| S:61 E:69 ||| VBN
from  ||| S:69 E:74 ||| IN
human  ||| S:74 E:80 ||| JJ
gastric  ||| S:80 E:88 ||| JJ
cancer  ||| S:88 E:95 ||| NN
tissues  ||| S:95 E:103 ||| NNS
and  ||| S:103 E:107 ||| CC
corresponding  ||| S:107 E:121 ||| JJ
ovarian  ||| S:121 E:129 ||| FW
metastases  ||| S:129 E:140 ||| FW
Mesenchymal  ||| S:140 E:152 ||| FW
stem  ||| S:152 E:157 ||| FW
cell  ||| S:157 E:162 ||| FW
( ||| S:162 E:163 ||| -LRB-
MSC ||| S:163 E:166 ||| NNP
) ||| S:166 E:167 ||| -RRB-
‑like  ||| S:167 E:173 ||| CD
cells  ||| S:173 E:179 ||| NNS
have  ||| S:179 E:184 ||| VBP
been  ||| S:184 E:189 ||| VBN
isolated  ||| S:189 E:198 ||| VBN
from  ||| S:198 E:203 ||| IN
various  ||| S:203 E:211 ||| JJ
types  ||| S:211 E:217 ||| NNS
of  ||| S:217 E:220 ||| IN
tumor ||| S:220 E:225 ||| NN
.  ||| S:225 E:227 ||| .
It  ||| S:227 E:230 ||| PRP
has  ||| S:230 E:234 ||| VBZ
previously  ||| S:234 E:245 ||| RB
been  ||| S:245 E:250 ||| VBN
reported  ||| S:250 E:259 ||| VBN
that  ||| S:259 E:264 ||| IN
MSCs  ||| S:264 E:269 ||| NNS
are  ||| S:269 E:273 ||| VBP
involved  ||| S:273 E:282 ||| VBN
in  ||| S:282 E:285 ||| IN
tumorigenesis  ||| S:285 E:299 ||| NN
and  ||| S:299 E:303 ||| CC
its  ||| S:303 E:307 ||| PRP$
prognosis ||| S:307 E:316 ||| NN
.  ||| S:316 E:318 ||| .
The  ||| S:318 E:322 ||| DT
aim  ||| S:322 E:326 ||| NN
of  ||| S:326 E:329 ||| IN
the  ||| S:329 E:333 ||| DT
present  ||| S:333 E:341 ||| JJ
study  ||| S:341 E:347 ||| NN
was  ||| S:347 E:351 ||| VBD
to  ||| S:351 E:354 ||| TO
isolate  ||| S:354 E:362 ||| VB
and  ||| S:362 E:366 ||| CC
compare  ||| S:366 E:374 ||| VB
MSC‑like  ||| S:374 E:383 ||| CD
cells  ||| S:383 E:389 ||| NNS
from  ||| S:389 E:394 ||| IN
human  ||| S:394 E:400 ||| JJ
gastric  ||| S:400 E:408 ||| JJ
cancer  ||| S:408 E:415 ||| NN
( ||| S:415 E:416 ||| -LRB-
GC ||| S:416 E:418 ||| NNP
)  ||| S:418 E:420 ||| -RRB-
and  ||| S:420 E:424 ||| CC
its  ||| S:424 E:428 ||| PRP$
metastatic  ||| S:428 E:439 ||| JJ
deposits  ||| S:439 E:448 ||| NNS
in  ||| S:448 E:451 ||| IN
ovarian  ||| S:451 E:459 ||| JJ
tissue ||| S:459 E:465 ||| NN
.  ||| S:465 E:467 ||| .
MSC‑like  ||| S:467 E:476 ||| NNP
cells  ||| S:476 E:482 ||| NNS
were  ||| S:482 E:487 ||| VBD
isolated  ||| S:487 E:496 ||| VBN
from  ||| S:496 E:501 ||| IN
human  ||| S:501 E:507 ||| JJ
gastric  ||| S:507 E:515 ||| JJ
cancer  ||| S:515 E:522 ||| NN
( ||| S:522 E:523 ||| -LRB-
hGC‑MSCs ||| S:523 E:531 ||| NNP
)  ||| S:531 E:533 ||| -RRB-
and  ||| S:533 E:537 ||| CC
the  ||| S:537 E:541 ||| DT
corresponding  ||| S:541 E:555 ||| JJ
ovarian  ||| S:555 E:563 ||| JJ
metastatic  ||| S:563 E:574 ||| JJ
tissues  ||| S:574 E:582 ||| NNS
( ||| S:582 E:583 ||| -LRB-
hGCOM‑MSCs ||| S:583 E:593 ||| NNP
)  ||| S:593 E:595 ||| -RRB-
from  ||| S:595 E:600 ||| IN
40 patients ||| S:600 E:611 ||| CD
.  ||| S:611 E:613 ||| .
The  ||| S:613 E:617 ||| DT
characteristics  ||| S:617 E:633 ||| NN
of  ||| S:633 E:636 ||| IN
hGC‑MSCs  ||| S:636 E:645 ||| NNP
and  ||| S:645 E:649 ||| CC
hGCOM‑MSCs ||| S:649 E:659 ||| NNP
,  ||| S:659 E:661 ||| ,
including  ||| S:661 E:671 ||| VBG
their  ||| S:671 E:677 ||| PRP$
morphology ||| S:677 E:687 ||| NN
,  ||| S:687 E:689 ||| ,
surface  ||| S:689 E:697 ||| NN
antigens ||| S:697 E:705 ||| NN
,  ||| S:705 E:707 ||| ,
specific  ||| S:707 E:716 ||| JJ
gene  ||| S:716 E:721 ||| NN
expression  ||| S:721 E:732 ||| NN
and  ||| S:732 E:736 ||| CC
differentiation  ||| S:736 E:752 ||| JJ
potential ||| S:752 E:761 ||| NN
,  ||| S:761 E:763 ||| ,
were  ||| S:763 E:768 ||| VBD
similar  ||| S:768 E:776 ||| JJ
to  ||| S:776 E:779 ||| TO
those  ||| S:779 E:785 ||| DT
of  ||| S:785 E:788 ||| IN
MSCs  ||| S:788 E:793 ||| JJ
derived  ||| S:793 E:801 ||| NN
from  ||| S:801 E:806 ||| IN
human  ||| S:806 E:812 ||| JJ
bone  ||| S:812 E:817 ||| NN
marrow  ||| S:817 E:824 ||| NNS
( ||| S:824 E:825 ||| -LRB-
hBM‑MSCs ||| S:825 E:833 ||| NNP
)  ||| S:833 E:835 ||| -RRB-
but  ||| S:835 E:839 ||| CC
different  ||| S:839 E:849 ||| JJ
from  ||| S:849 E:854 ||| IN
GC  ||| S:854 E:857 ||| NNP
cells ||| S:857 E:862 ||| NNS
.  ||| S:862 E:864 ||| .
In  ||| S:864 E:867 ||| IN
conclusion ||| S:867 E:877 ||| NN
,  ||| S:877 E:879 ||| ,
the  ||| S:879 E:883 ||| DT
present  ||| S:883 E:891 ||| JJ
study  ||| S:891 E:897 ||| NN
demonstrated  ||| S:897 E:910 ||| VBN
that  ||| S:910 E:915 ||| IN
MSC‑like  ||| S:915 E:924 ||| CD
cells  ||| S:924 E:930 ||| NNS
could  ||| S:930 E:936 ||| MD
be  ||| S:936 E:939 ||| VB
isolated  ||| S:939 E:948 ||| VBN
from  ||| S:948 E:953 ||| IN
GC  ||| S:953 E:956 ||| NNP
tissue  ||| S:956 E:963 ||| NN
and  ||| S:963 E:967 ||| CC
its  ||| S:967 E:971 ||| PRP$
ovarian  ||| S:971 E:979 ||| JJ
metastatic  ||| S:979 E:990 ||| JJ
tissues ||| S:990 E:997 ||| NNS
.  ||| S:997 E:999 ||| .
The  ||| S:999 E:1003 ||| DT
existence  ||| S:1003 E:1013 ||| NN
of  ||| S:1013 E:1016 ||| IN
MSC‑like  ||| S:1016 E:1025 ||| CD
cells  ||| S:1025 E:1031 ||| NNS
in  ||| S:1031 E:1034 ||| IN
GC  ||| S:1034 E:1037 ||| NNP
tissues  ||| S:1037 E:1045 ||| NNS
and  ||| S:1045 E:1049 ||| CC
its  ||| S:1049 E:1053 ||| PRP$
ovarian  ||| S:1053 E:1061 ||| JJ
metastatic  ||| S:1061 E:1072 ||| JJ
tissues  ||| S:1072 E:1080 ||| NNS
suggests  ||| S:1080 E:1089 ||| VBZ
that  ||| S:1089 E:1094 ||| IN
they  ||| S:1094 E:1099 ||| PRP
may  ||| S:1099 E:1103 ||| MD
be  ||| S:1103 E:1106 ||| VB
a  ||| S:1106 E:1108 ||| DT
potential  ||| S:1108 E:1118 ||| JJ
target  ||| S:1118 E:1125 ||| NN
for  ||| S:1125 E:1129 ||| IN
cancer  ||| S:1129 E:1136 ||| NN
therapy ||| S:1136 E:1143 ||| NN
,  ||| S:1143 E:1145 ||| ,
and  ||| S:1145 E:1149 ||| CC
provides  ||| S:1149 E:1158 ||| VBZ
an  ||| S:1158 E:1161 ||| DT
experimental  ||| S:1161 E:1174 ||| JJ
foundation  ||| S:1174 E:1185 ||| NN
for  ||| S:1185 E:1189 ||| IN
investigating  ||| S:1189 E:1203 ||| VBG
their  ||| S:1203 E:1209 ||| PRP$
role  ||| S:1209 E:1214 ||| NN
in  ||| S:1214 E:1217 ||| IN
the  ||| S:1217 E:1221 ||| DT
initiation  ||| S:1221 E:1232 ||| NN
and  ||| S:1232 E:1236 ||| CC
progression  ||| S:1236 E:1248 ||| NN
of  ||| S:1248 E:1251 ||| IN
ovarian  ||| S:1251 E:1259 ||| JJ
metastasis  ||| S:1259 E:1270 ||| NN
of  ||| S:1270 E:1273 ||| IN
GC ||| S:1273 E:1275 ||| NNP
.  ||| S:1275 E:1277 ||| .
